MedPath

ResQ Pharma's LipidRescue Receives FDA PDUFA Date for LAST Treatment

• ResQ Pharma's LipidRescue Kit has been granted a PDUFA date of June 2, 2025, by the FDA, marking a significant step toward potential approval. • LipidRescue is designed as a drug/device combination to rapidly administer lipid emulsion, counteracting the toxicity of local anesthetics in LAST. • The LipidRescue Kit aims to standardize and simplify the treatment of LAST, offering a pre-packaged solution with clear instructions for healthcare providers. • If approved, LipidRescue would be the first FDA-approved treatment specifically designed for Local Anesthetic Systemic Toxicity (LAST).

ResQ Pharma, Inc. has announced that the FDA has set a Prescription Drug User Fee Act (PDUFA) date of June 2, 2025, for its LipidRescue Kit. This kit is designed to treat Local Anesthetic Systemic Toxicity (LAST), a rare but potentially fatal condition that can arise from the use of local anesthetics like lidocaine. If approved, LipidRescue would be the first FDA-approved treatment specifically for LAST.

Addressing a Critical Unmet Need in Anesthesia

LAST is a life-threatening event characterized by symptoms such as altered mental status, cardiac instability, seizures, coma, respiratory or cardiac arrest, and potentially death. It can occur in various healthcare settings where local anesthetics are administered. Current treatment involves the infusion of lipid emulsion, a practice supported by clinical guidelines and extensive preclinical and clinical data. However, LipidRescue aims to improve upon this standard by providing a standardized, readily available kit.

LipidRescue: A Novel Drug-Device Combination

LipidRescue comprises a soybean oil emulsion to mitigate the toxic effects of local anesthetic overdose, along with a purpose-designed administration set. This set facilitates rapid and accurate administration of the lipid emulsion through existing vascular access, eliminating the need for needles to draw lipid from bags. The kit also includes a quick reference guide with clear instructions, crucial for timely intervention when seconds matter.

Expert Perspectives on LipidRescue

Dr. Guy Weinberg, Founder and President of ResQ Pharma and the inventor of LipidRescue Therapy (LRT), stated, "Since discovering more than 25 years ago that lipid emulsion infusion could reverse catastrophic reactions to local anesthetics, I have looked forward to the day that this novel therapy would become a widely available, standardized treatment for a dangerous and potentially fatal condition."

The Significance of the PDUFA Date

The assignment of a PDUFA date signifies that the New Drug Application (NDA) is sufficiently complete for substantive review. This provides a timeline for when the review should be completed, marking a crucial milestone in the drug development process. Mukesh Kumar of FDAMap, who consulted on the NDA preparation, and Michael Gaba of Polsinelli's FDA practice group, are also key figures in ResQ Pharma's regulatory efforts.

ResQ Pharma's Vision for LipidRescue

ResQ Pharma envisions LipidRescue as a means to ensure reliable, global use of LRT, not only for LAST but also potentially for other lipophilic drug overdoses and poisonings. The company, founded by Dr. Weinberg, is dedicated to commercializing his research findings on the mechanisms and treatment of local anesthetic toxicity.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

SQ Innovation's Lasix ONYU Receives Tentative FDA Approval for Congestive Heart Failure Treatment

SQ Innovation's Lasix ONYU, a combination of furosemide and an on-body device, receives tentative FDA approval for treating fluid overload in congestive heart failure.
The device, developed with Gerresheimer, allows precise, controlled drug administration and is designed for patient comfort and environmental sustainability.

FDA Approves Revumenib for Relapsed or Refractory Acute Leukemia with KMT2A Translocation

The FDA has approved revumenib for relapsed or refractory acute leukemia with KMT2A translocation, offering a new treatment option.
Revumenib's approval is based on clinical trials demonstrating improved remission rates and overall survival in patients with this aggressive leukemia.

FDA Sets New Review Date for Reproxalap in Dry Eye Disease

The FDA has accepted the resubmitted NDA for reproxalap, a potential treatment for dry eye disease, with a PDUFA date set for April 2, 2025.
Reproxalap, developed by Aldeyra Therapeutics, is a first-in-class small-molecule modulator of RASP, targeting inflammation caused by reactive aldehyde species.

FDA Approves Revuforj (revumenib) for Relapsed or Refractory Acute Leukemia with KMT2A Translocation

The FDA has approved Revuforj (revumenib) as the first and only menin inhibitor for relapsed or refractory acute leukemia with KMT2A translocation.
Approval was based on the AUGMENT-101 trial, which showed robust remission rates in acute leukemia patients with KMT2A translocation.

FDA Accepts Dupixent sBLA for Chronic Spontaneous Urticaria Treatment

The FDA has accepted the resubmitted sBLA for Dupixent to treat chronic spontaneous urticaria (CSU) in patients 12 years and older whose condition is not adequately controlled by H1 antihistamines.
The sBLA is supported by data from the LIBERTY-CUPID phase 3 clinical program, which demonstrated significant reductions in itch and urticaria activity with Dupixent.

FDA Accepts Dupixent sBLA for Chronic Spontaneous Urticaria Treatment

The FDA has accepted the resubmitted sBLA for Dupixent to treat chronic spontaneous urticaria (CSU) in patients 12 years and older uncontrolled by antihistamines.
The sBLA is supported by data from the LIBERTY-CUPID phase 3 program, demonstrating significant reductions in itch and urticaria activity.

FDA Accepts Unicycive's Oxylanthanum Carbonate (OLC) Application for Hyperphosphatemia Treatment

The FDA has accepted Unicycive Therapeutics' NDA for Oxylanthanum Carbonate (OLC) for treating hyperphosphatemia in chronic kidney disease patients on dialysis.
The FDA has set a PDUFA target action date of June 28, 2025, for OLC, a next-generation lanthanum-based phosphate binding agent.

R3 Vascular's MAGNITUDE Scaffold Receives FDA Approval for BTK PAD Trial

The FDA has approved R3 Vascular to begin the ELITE-BTK trial for its MAGNITUDE drug-eluting bioresorbable scaffold, targeting below-the-knee peripheral arterial disease.
The MAGNITUDE scaffold, made from ultra-high molecular weight polylactic acid polymer, is designed to gradually absorb into the tissue while providing structural support.

FDA Grants Priority Review for Indivior's SUBLOCADE® Expansion

The FDA granted Priority Review to Indivior's sNDA for SUBLOCADE®, setting a PDUFA date of February 7, 2025.
The sNDA seeks approval for alternative injection sites (thigh, buttock, back of the arm) for both induction and maintenance.

Verastem Oncology's Avutometinib and Defactinib Combination Receives FDA Priority Review for Recurrent KRAS Mutant LGSOC

The FDA has accepted Verastem Oncology's NDA for avutometinib plus defactinib with Priority Review for recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC).
The PDUFA target action date is set for June 30, 2025, potentially bringing the first FDA-approved treatment for this specific LGSOC subtype.

Reference News

[1]
ResQ Pharma Receives PDUFA Date for LipidRescue™ as a Potential First-Ever, FDA ...
morningstar.com · Nov 11, 2024

ResQ Pharma receives PDUFA date of June 2, 2025, for LipidRescue™, a potential FDA-approved treatment for Local Anesthet...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy